BUKWANG PHARMACEUTICAL IND CO.,LTD
Financials
Valuation Metrics
BUKWANG PHARMACEUTICAL IND CO.,LTD's Market Cap is ₩3660B. At end of 2025 it was ₩3734B. Ranked #544 of 2,410 in KR market (top 23%), #329 of 779 on KOSPI (top 42%), #57 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 366.05B KRW | KR#544/2,410 Sec#57/231 |
| Revenue | 215.09B KRW | KR#988/2,410 Sec#55/231 |
| Net Income | 8.70B KRW | KR#1,017/2,410 Sec#63/231 |
| Total Assets | 467.05B KRW | KR#800/2,410 Sec#48/231 |
| Net Assets | 334.39B KRW | KR#678/2,410 Sec#44/231 |
| Employees | 582 | KR#426/2,410 Sec#37/231 |
| Value | ||
| P/E | 42.07x | KR#1,396/2,410 Sec#89/231 |
| P/B | 1.09x | KR#1,609/2,410 Sec#102/231 |
| P/S | 1.70x | KR#1,771/2,410 Sec#102/231 |
| EV/EBITDA | 29.33x | KR#1,206/2,410 Sec#74/231 |
| FCF Yield | 3.88% | KR#948/2,410 Sec#58/231 |
| Profitability | ||
| ROE | 2.60% | KR#1,352/2,410 Sec#93/231 |
| ROA | 1.86% | KR#1,245/2,410 Sec#89/231 |
| Op. Margin | 5.42% | KR#911/2,410 Sec#69/231 |
| Revenue Growth | 20.05% | KR#549/2,410 Sec#52/231 |
| Earnings Growth | -31.88% | KR#991/2,410 Sec#64/231 |
| Financial Health | ||
| Debt Ratio | 39.67% | KR#780/2,410 Sec#91/231 |
| Total Debt | 79.82B KRW | KR#804/2,410 Sec#50/231 |
| FCF | 14.21B KRW | KR#618/2,410 Sec#33/231 |
| Cash | 104.10B KRW | KR#461/2,410 Sec#22/231 |
| Current Ratio | 2.33x | KR#742/2,410 Sec#88/231 |
| Net Debt/EBITDA | -2.08x | KR#227/2,410 Sec#9/231 |
| Dividend | ||
| Div. Yield | 3.38% | KR#601/2,410 Sec#26/231 |
| Performance | ||
| 1Y Return | 0.41% | KR#567/2,410 Sec#32/231 |
| 1M Return | -9.51% | KR#1,108/2,410 Sec#108/231 |
| From 52W High | -62.49% | KR#1,755/2,410 Sec#146/231 |
| 1Y MDD | -61.88% | KR#1,544/2,410 Sec#125/231 |
| Trading | ||
| Volume | 125,029 shares | KR#361/2,410 Sec#36/231 |
| Trading Value | 461.9M KRW | KR#676/2,410 Sec#68/231 |
| Foreign Own. | 6.77% | KR#657/2,410 Sec#57/231 |
| Per Share | ||
| EPS | 88 KRW | KR#1,449/2,410 Sec#98/231 |
| BPS | 3,389 KRW | KR#1,785/2,410 Sec#134/231 |
Company Info
Bugwang Pharm, established in 1960 for the purpose of manufacturing and selling pharmaceuticals, was listed on the Securities Market in 1988. The company holds four unlisted subsidiaries, including Denmark-based Contera Pharma A/S, Bugwang Medica Co., Ltd., JaguAHR Therapeutics, and ProteKt Therapeutics. It engages in the manufacturing and sales of pharmaceuticals and quasi-drugs, with major products including Dexid, Ferroba, Legalon, Latuda, and Tasenol. Bugwang Pharm is headquartered in Dongjak-gu, Seoul.